Cargando…
PTPRT and PTPRD Deleterious Mutations and Deletion Predict Bevacizumab Resistance in Metastatic Colorectal Cancer Patients
Background: Bevacizumab-based regimens are used as standard treatments for colorectal cancer. Unfortunately, there are no established predictive markers for bevacizumab response. Methods: Tumor samples from 36 metastatic colorectal cancer patients treated with bevacizumab plus chemotherapy were anal...
Autores principales: | Hsu, Hung-Chih, Lapke, Nina, Chen, Shu-Jen, Lu, Yen-Jung, Jhou, Ren-Shiang, Yeh, Chien-Yuh, Tsai, Wen-Sy, Hung, Hsin-Yuan, Hsieh, Jason Chia-Hsun, Yang, Tsai-Sheng, Thiam, Tan Kien, You, Jeng-Fu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162606/ https://www.ncbi.nlm.nih.gov/pubmed/30200630 http://dx.doi.org/10.3390/cancers10090314 |
Ejemplares similares
-
TP53 DNA Binding Domain Mutations Predict Progression-Free Survival of Bevacizumab Therapy in Metastatic Colorectal Cancer
por: Hsu, Hung-Chih, et al.
Publicado: (2019) -
Association of PTPRD/PTPRT Mutation With Better Clinical Outcomes in NSCLC Patients Treated With Immune Checkpoint Blockades
por: Wang, Xiaoyan, et al.
Publicado: (2021) -
PTPRD/PTPRT mutation as a predictive biomarker of immune checkpoint inhibitors across multiple cancer types
por: Shang, Xiaoling, et al.
Publicado: (2022) -
Deletion of Ptprd and Cdkn2a cooperate to accelerate tumorigenesis
por: Ortiz, Berenice, et al.
Publicado: (2014) -
Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients
por: Hsu, Hung-Chih, et al.
Publicado: (2016)